REGENXBIO

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell REGENXBIO and other ETFs, options, and stocks.

About RGNX

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. 

CEO
Curran M. Simpson
CEOCurran M. Simpson
Employees
371
Employees371
Headquarters
Rockville, Maryland
HeadquartersRockville, Maryland
Founded
2008
Founded2008
Employees
371
Employees371

RGNX Key Statistics

Market cap
483.61M
Market cap483.61M
Price-Earnings ratio
-2.50
Price-Earnings ratio-2.50
Dividend yield
Dividend yield
Average volume
1.14M
Average volume1.14M
High today
$10.05
High today$10.05
Low today
$9.15
Low today$9.15
Open price
$9.79
Open price$9.79
Volume
726.32K
Volume726.32K
52 Week high
$16.19
52 Week high$16.19
52 Week low
$5.04
52 Week low$5.04

Stock Snapshot

As of today, REGENXBIO(RGNX) shares are valued at $9.41. The company's market cap stands at 483.61M, with a P/E ratio of -2.50.

During the trading session on 2026-03-12, REGENXBIO(RGNX) shares reached a daily high of $10.05 and a low of $9.15. At a current price of $9.41, the stock is +2.8% higher than the low and still -6.4% under the high.

Trading activity shows a volume of 726.32K, compared to an average daily volume of 1.14M.

The stock's 52-week range extends from a low of $5.04 to a high of $16.19.

The stock's 52-week range extends from a low of $5.04 to a high of $16.19.

RGNX News

TipRanks 5d
RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty

RegenXBio Inc. (RGNX) has disclosed a new risk, in the Innovation / R&D category. RegenXbio Inc. faces heightened development and regulatory risk because the F...

TipRanks 6d
Buy These 3 Best Stocks Now, According to Top Wall Street Analysts, 3/6/2026

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating rec...

TipRanks 6d
RegenXBio Earnings Call Balances Gene Therapy Risks

RegenXBio Inc. ((RGNX)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 70% Off TipRanks Premium Unlock hedge fund-level data...

Analyst ratings

92%

of 12 ratings
Buy
91.7%
Hold
8.3%
Sell
0%

More RGNX News

TipRanks 7d
Regenxbio reports Q4 EPS ($1.30) vs. ($1.01) last year

Reports Q4 revenue $30.3M vs. $21.2M last year. “We are rapidly advancing our late-stage pipeline of gene therapies to treat rare and retinal diseases with sign...

People also own

Based on the portfolios of people who own RGNX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.